Clinical Trial: Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional
Official Title: Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Brief Summary:
Background:
Proteus syndrome (PS) is caused by a mutation in the AKT1 gene. This gene makes a protein that communicates with other proteins in the body to make cells grow. The AKT1 mutation changes chemical signals in the body and causes overgrowth. PS can be fatal. The drug ARQ 092 reduces signals from the AKT1 protein. This may reduce or stabilize some of the overgrowth in people with PS. Researchers want to find the best dose of ARQ 092 based on its effect on tissues in people with PS.
Objective:
To determine the safety, tolerability, and recommended dose of ARQ 092 in people with PS.
Eligibility:
People ages 6 and older with PS
Design:
Participants will be screened with medical history, physical exam, and blood and urine tests.
Participants will take ARQ 092 by mouth once daily for up to 12 28-day cycles.
Participants must stay near the NIH Clinical Center (CC) during the whole first cycle, for weekly visits to the CC. For cycle 2, they will have visits every 2 weeks. They will have 1 visit before cycles 3 and 4, and once before every other cycle for cycles 5 11. The final visit will be at the end of cycle 12. Visits may include:
Small skin samples taken.
ECG: Soft electrodes on the skin record heart signals.
Echocardiogram: A small probe held to the chest takes pictures of the heart.
Original Primary Outcome: Same as current
Current Secondary Outcome: Tolerability and side effects [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: National Institutes of Health Clinical Center (CC)
Dates:
Date Received: October 31, 2015
Date Started: October 29, 2015
Date Completion: December 31, 2017
Last Updated: May 12, 2017
Last Verified: April 18, 2017
